Is Hims & Hers Health Stock a Buy?
Established in 2017, Hims & Hers Health (NYSE: HIMS) is a relatively young company addressing age-old healthcare challenges by offering prescription medications, over-the-counter products, and personal care solutions through a convenient direct-to-consumer model. Since going public via a special purpose acquisition company (SPAC) merger in 2021, the telehealth company and its stock have experienced dramatic transformations.
Following the merger, the stock traded somewhat volatilely but on a downward trend for much of 2021 and part of 2022, reaching an all-time low of $2.72 per share in 2022. It has recovered since then and hit an all-time high of $35.02 per share in late 2024. Since then, the price saw additional volatility and now trades around $30.73 a share. Meanwhile, the business continues to report surging subscriber growth and increasing revenue.
Let's take a closer look at how the company is performing today and whether the stock is a buy, sell, or hold for long-term investors.
Source Fool.com
